Targretin bexarotene gel regulatory update

The FDA granted priority review status to LGND's NDA, submitted last December, for its Targretin 1 percent gel to treat cutaneous T cell lymphoma (CTCL) (see BioCentury, Dec. 13, 1999). LGND's Targre...